Zoetis Inc. (NYSE:ZTS) Shares Bought by William Allan Corp

William Allan Corp boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 100.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 28,892 shares of the company’s stock after purchasing an additional 14,468 shares during the quarter. Zoetis comprises 3.4% of William Allan Corp’s holdings, making the stock its 10th largest holding. William Allan Corp’s holdings in Zoetis were worth $5,645,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Darwin Wealth Management LLC purchased a new stake in Zoetis in the 3rd quarter valued at about $31,000. First Personal Financial Services bought a new position in shares of Zoetis in the third quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new position in shares of Zoetis in the third quarter valued at approximately $33,000. Quarry LP increased its position in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares during the last quarter. Finally, LRI Investments LLC bought a new stake in Zoetis during the first quarter worth $43,000. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Up 0.6 %

Zoetis stock opened at $176.74 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The stock has a market capitalization of $79.74 billion, a PE ratio of 33.22, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90. The business’s fifty day moving average is $184.18 and its 200 day moving average is $180.78. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm earned $1.36 earnings per share. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, sell-side analysts predict that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s payout ratio is currently 32.52%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Piper Sandler boosted their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Stifel Nicolaus boosted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Zoetis currently has an average rating of “Buy” and an average target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.